Trinity Biotech Valuation

Is TRIB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TRIB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TRIB ($1.13) is trading below our estimate of fair value ($6.79)

Significantly Below Fair Value: TRIB is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TRIB?

Key metric: As TRIB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TRIB. This is calculated by dividing TRIB's market cap by their current revenue.
What is TRIB's PS Ratio?
PS Ratio	0.2x
Sales	US$59.13m
Market Cap	US$11.55m

TRIB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.7x
Enterprise Value/EBITDA	-11.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does TRIB's PS Ratio compare to its peers?

The above table shows the PS ratio for TRIB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.1x
NURO NeuroMetrix	2.3x	n/a	US$8.7m
SSKN STRATA Skin Sciences	0.4x	8.0%	US$12.7m
HLTH Cue Health	0.2x	38.4%	US$14.7m
AWH Aspira Women's Health	1.3x	57.8%	US$12.0m
TRIB Trinity Biotech	0.2x	11.8%	US$11.5m

Price-To-Sales vs Peers: TRIB is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (1.1x).

Price to Sales Ratio vs Industry

How does TRIB's PS Ratio compare vs other companies in the US Medical Equipment Industry?

54 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	3.3x	8.2%
TRIB Trinity Biotech	0.2x	11.8%	US$11.55m
EMBC Embecta	0.7x	1.3%	US$797.44m
INGN Inogen	0.7x	4.2%	US$223.42m

54 Companies		Estimated Growth	Market Cap
Industry Avg.	3.3x	17.1%
TRIB Trinity Biotech	0.2x	33.2%	US$11.55m

No more companies

Price-To-Sales vs Industry: TRIB is good value based on its Price-To-Sales Ratio (0.2x) compared to the US Medical Equipment industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is TRIB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TRIB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.2x
Fair PS Ratio	0.4x

Price-To-Sales vs Fair Ratio: TRIB is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (0.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.52

18.8%

27.5%

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

ELV

US$402.55

0.5%

-15.7%

electroCore

US$72.3m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.21

16.2%

99.5%